Investigating Myosteatosis in Steatotic Liver Diseases

Steatotic liver diseases (SLD) are the most common chronic liver diseases worldwide. SLD are defined by an excessive liver lipid content (steatosis) of more than 5% of the total liver weight and includes 3 clinical entities : metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD) and a mixed entity combining the two settings referred as MetALD. SLD are associated to extra-hepatic complications such as cardiovascular diseases, insulin resistance or muscle changes. Among the latter, myosteatosis, defined by an excessive muscle fat content, has been reported as a muscle change in MASLD occuring even in non-cirrhotic stages. Investigators will explore these muscle changes in SLD patients according to the severity of the underneath liver disease.

NCT Number	NCT06514300
Lead Sponsor	Cliniques universitaires Saint-Luc- Université Catholique de Louvain Collaborators: Fonds National de la Recherche Scientifique, Concerted Research Action
Conditions	Alcohol-related Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease of Mixed Origin (MetALD), Steatotic Liver Diseases, Myosteatosis, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Liver Histology
Enrollment	100 participants
Start Date	2020-06-22
Primary Completion	2024-08 (estimated)
Study Completion	2024-08 (estimated)
Updated on ClinicalTrials.gov	2024-07-23